

Harlan F Weisman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11296608/publications.pdf>

Version: 2024-02-01

15
papers

1,958
citations

758635

12
h-index

1058022

14
g-index

18
all docs

18
docs citations

18
times ranked

606
citing authors

#	ARTICLE	IF	CITATIONS
1	Pharmacodynamic Profile of Short-term Abciximab Treatment Demonstrates Prolonged Platelet Inhibition With Gradual Recovery From GP IIb/IIIa Receptor Blockade. <i>Circulation</i> , 1998, 97, 1680-1688.	1.6	282
2	Bleeding Complications With the Chimeric Antibody to Platelet Glycoprotein IIb/IIIa Integrin in Patients Undergoing Percutaneous Coronary Intervention. <i>Circulation</i> , 1995, 91, 2882-2890.	1.6	216
3	Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (Abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. <i>American Journal of Cardiology</i> , 1996, 77, 1045-1051.	0.7	205
4	Evidence for Prevention of Death and Myocardial Infarction With Platelet Membrane Glycoprotein IIb/IIIa Receptor Blockade by Abciximab (c7E3 Fab) Among Patients With Unstable Angina Undergoing Percutaneous Coronary Revascularization. <i>Journal of the American College of Cardiology</i> , 1997, 30, 149-156. This study was supported by Centocor, Inc., Malvern, Pennsylvania.	1.2	204
5	Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: Implications for inhibition of the internal pool of GPIIb/IIIa receptors. <i>Journal of the American College of Cardiology</i> , 1995, 26, 1665-1671.	1.2	158
6	Sustained Suppression of Ischemic Complications of Coronary Intervention by Platelet GP IIb/IIIa Blockade With Abciximab. <i>Circulation</i> , 1999, 99, 1951-1958.	1.6	154
7	Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). <i>American Journal of Cardiology</i> , 1995, 75, 559-562.	0.7	147
8	Monoclonal Antibodies to Platelet Glycoprotein IIb/IIIa as Antithrombotic Agents. <i>Annals of the New York Academy of Sciences</i> , 1991, 614, 193-213.	1.8	145
9	Standard Versus Low-Dose Weight-Adjusted Heparin in Patients Treated With the Platelet Glycoprotein IIb/IIIa Receptor Antibody Fragment Abciximab (c7E3 Fab) During Percutaneous Coronary Revascularization. <i>American Journal of Cardiology</i> , 1997, 79, 286-291.	0.7	137
10	Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention. <i>Journal of the American College of Cardiology</i> , 2001, 37, 2059-2065.	1.2	136
11	The immunogenicity of the 7E3 murine monoclonal Fab antibody fragment variable region is dramatically reduced in humans by substitution of human for murine constant regions. <i>Molecular Immunology</i> , 1995, 32, 1271-1281.	1.0	118
12	Therapeutic heparin concentrations augment platelet reactivity: Implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab. <i>American Heart Journal</i> , 2000, 139, 696-703.	1.2	42
13	Concept and Clinical Application of Platelet Glycoprotein IIb/IIIa Inhibition with Abciximab (c7E3 Fab); Tj ETQq1 1 0.784314 rgBT /Ove 1997, 3, 256-266.	0.7	7
14	An industry perspective on health economics studies. <i>American Heart Journal</i> , 1999, 137, S129-S132.	1.2	3
15	Abciximab: The First Platelet Glycoprotein IIb/IIIa Receptor Antagonist. , 1999, , 35-71.		2